PL3607068T3 - Hamowanie TMPRSS6 mediowane interferencją RNA - Google Patents

Hamowanie TMPRSS6 mediowane interferencją RNA

Info

Publication number: PL3607068T3
Authority: PL; Poland
Prior art keywords: tmprss6; rna interference; mediated inhibition; interference mediated; inhibition
Prior art date: 2017-04-05

Application number

PL18715705.2T

Other languages

English (en)

Inventor

Sibylle DAMES

Ute SCHAEPER

Judith HAUPTMANN

Christian Frauendorf

Lucas Bethge

Adrien WEINGÄRTNER

Original Assignee

Silence Therapeutics Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-05

Filing date

2018-04-05

Publication date

2023-03-20

2017-04-05 Priority claimed from EP17165007.0A external-priority patent/EP3385380A1/en

2018-04-05 Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh

2023-03-20 Publication of PL3607068T3 publication Critical patent/PL3607068T3/pl

Links

238000012228 RNA interference-mediated gene silencing Methods 0.000 title 1
230000009368 gene silencing by RNA Effects 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
230000001404 mediated effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Diabetes (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL18715705.2T 2017-04-05 2018-04-05 Hamowanie TMPRSS6 mediowane interferencją RNA PL3607068T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP17165007.0A EP3385380A1 (en)	2017-04-05	2017-04-05	Products and compositions
EP17201405		2017-11-13
PCT/EP2018/058764 WO2018185240A1 (en)	2017-04-05	2018-04-05	Products and compositions

Publications (1)

Publication Number	Publication Date
PL3607068T3 true PL3607068T3 (pl)	2023-03-20

Family

ID=61899310

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18715705.2T PL3607068T3 (pl)	2017-04-05	2018-04-05	Hamowanie TMPRSS6 mediowane interferencją RNA

Country Status (18)

Country	Link
US (2)	US11174483B2 (pl)
EP (2)	EP3607068B1 (pl)
JP (4)	JP7247167B2 (pl)
KR (1)	KR102589803B1 (pl)
CN (2)	CN110573619A (pl)
AU (2)	AU2018247924B2 (pl)
CA (2)	CA3057561A1 (pl)
DK (1)	DK3607068T3 (pl)
ES (1)	ES2936109T3 (pl)
FI (1)	FI3607068T3 (pl)
HR (1)	HRP20221547T1 (pl)
HU (1)	HUE061894T2 (pl)
IL (2)	IL269576B2 (pl)
LT (1)	LT3607068T (pl)
PL (1)	PL3607068T3 (pl)
RS (1)	RS63887B1 (pl)
SI (1)	SI3607068T1 (pl)
WO (1)	WO2018185240A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11414660B2 (en)	2017-04-05	2022-08-16	Silence Therapeutics Gmbh	Products and compositions
AU2018247925B2 (en) *	2017-04-05	2024-06-06	Silence Therapeutics Gmbh	Products and compositions
EP3598995A1 (en) *	2018-07-26	2020-01-29	Silence Therapeutics GmbH	Products and compositions
CN111973619B (zh) *	2019-05-23	2024-01-30	苏州瑞博生物技术股份有限公司	核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
CA3216859A1 (en) *	2021-04-27	2022-11-03	Silence Therapeutics Gmbh	Sirna targeting tmprss6 for the treatment of myeloproliferative disorders
TW202400193A (zh)	2022-06-24	2024-01-01	丹麥商諾佛儂迪克股份有限公司	抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
WO2024060649A1 (zh) *	2022-09-29	2024-03-28	广州必贝特医药股份有限公司	用于抑制TMPRSS6基因表达的siRNA或其盐、药物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL9201440A (nl)	1992-08-11	1994-03-01	Univ Leiden	Triantennaire clusterglycosiden, hun bereiding en toepassing.
EP2305812A3 (en) *	2002-11-14	2012-06-06	Dharmacon, Inc.	Fuctional and hyperfunctional sirna
EP2601204B1 (en) *	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modified nucleosides and oligomeric compounds prepared therefrom
SG10201602369PA (en) *	2011-03-29	2016-05-30	Alnylam Pharmaceuticals Inc	Double-Stranded RNA (dsRNA) For Inhibiting Expression Of TMPRSS6
ES2761343T3 (es) *	2011-11-07	2020-05-19	Ionis Pharmaceuticals Inc	Modulación de la expresión de TMPRSS6
MY181888A (en) *	2013-05-22	2021-01-12	Alnylam Pharmaceuticals Inc	Tmprss6 irna compositions and methods of use thereof
US10233448B2 (en) *	2014-08-20	2019-03-19	Alnylam Pharmaceuticals, Inc.	Modified double-stranded RNA agents
WO2016085852A1 (en) *	2014-11-24	2016-06-02	Alnylam Pharmaceuticals, Inc.	Tmprss6 irna compositions and methods of use thereof
WO2016149020A1 (en) *	2015-03-17	2016-09-22	Arrowhead Research Corporation	Rna interference agents
EP3228326A1 (en)	2016-04-05	2017-10-11	Silence Therapeutics GmbH	Nucleic acid linked to a trivalent glycoconjugate

2018
- 2018-04-05 HU HUE18715705A patent/HUE061894T2/hu unknown
- 2018-04-05 LT LTEPPCT/EP2018/058764T patent/LT3607068T/lt unknown
- 2018-04-05 ES ES18715705T patent/ES2936109T3/es active Active
- 2018-04-05 DK DK18715705.2T patent/DK3607068T3/da active
- 2018-04-05 RS RS20230024A patent/RS63887B1/sr unknown
- 2018-04-05 FI FIEP18715705.2T patent/FI3607068T3/fi active
- 2018-04-05 PL PL18715705.2T patent/PL3607068T3/pl unknown
- 2018-04-05 SI SI201830837T patent/SI3607068T1/sl unknown
- 2018-04-05 CA CA3057561A patent/CA3057561A1/en active Pending
- 2018-04-05 KR KR1020197032297A patent/KR102589803B1/ko active IP Right Grant
- 2018-04-05 CN CN201880021535.3A patent/CN110573619A/zh active Pending
- 2018-04-05 AU AU2018247924A patent/AU2018247924B2/en active Active
- 2018-04-05 IL IL269576A patent/IL269576B2/en unknown
- 2018-04-05 EP EP18715705.2A patent/EP3607068B1/en active Active
- 2018-04-05 EP EP22202522.3A patent/EP4219714A3/en active Pending
- 2018-04-05 US US16/500,703 patent/US11174483B2/en active Active
- 2018-04-05 HR HRP20221547TT patent/HRP20221547T1/hr unknown
- 2018-04-05 WO PCT/EP2018/058764 patent/WO2018185240A1/en unknown
- 2018-04-05 JP JP2020504435A patent/JP7247167B2/ja active Active
2019
- 2019-04-05 AU AU2019247637A patent/AU2019247637A1/en active Pending
- 2019-04-05 CN CN201980037644.9A patent/CN112424354A/zh active Pending
- 2019-04-05 JP JP2020554254A patent/JP7419252B2/ja active Active
- 2019-04-05 CA CA3095523A patent/CA3095523A1/en active Pending
2020
- 2020-09-29 IL IL277636A patent/IL277636A/en unknown
2021
- 2021-10-05 US US17/450,064 patent/US20220025377A1/en active Pending
2023
- 2023-03-14 JP JP2023039774A patent/JP7495544B2/ja active Active
2024
- 2024-01-09 JP JP2024001366A patent/JP2024036347A/ja active Pending

Also Published As

Publication number	Publication date
EP4219714A2 (en)	2023-08-02
HRP20221547T1 (hr)	2023-03-03
US20220025377A1 (en)	2022-01-27
EP3607068A1 (en)	2020-02-12
JP2021520207A (ja)	2021-08-19
EP4219714A3 (en)	2023-08-30
SI3607068T1 (sl)	2023-02-28
HUE061894T2 (hu)	2023-08-28
IL269576B1 (en)	2024-02-01
JP7419252B2 (ja)	2024-01-22
RS63887B1 (sr)	2023-02-28
CA3095523A1 (en)	2019-10-10
CN110573619A (zh)	2019-12-13
BR112019019921A2 (pt)	2020-04-22
IL269576A (en)	2019-11-28
JP7495544B2 (ja)	2024-06-04
US20200208158A1 (en)	2020-07-02
AU2018247924B2 (en)	2023-02-02
AU2019247637A1 (en)	2020-10-22
US11174483B2 (en)	2021-11-16
DK3607068T3 (da)	2023-01-23
KR20190137842A (ko)	2019-12-11
JP7247167B2 (ja)	2023-03-28
IL269576B2 (en)	2024-06-01
ES2936109T3 (es)	2023-03-14
WO2018185240A1 (en)	2018-10-11
JP2023068035A (ja)	2023-05-16
CN112424354A (zh)	2021-02-26
EP3607068B1 (en)	2022-11-02
AU2018247924A1 (en)	2019-11-14
CA3057561A1 (en)	2018-10-11
IL277636A (en)	2020-11-30
JP2020512838A (ja)	2020-04-30
FI3607068T3 (fi)	2023-02-19
LT3607068T (lt)	2023-02-10
KR102589803B1 (ko)	2023-10-16
JP2024036347A (ja)	2024-03-15

Publication	Publication Date	Title
ZA201803436B (en)	2021-01-27	Inhibitors of cxcr2
EP3541932A4 (en)	2021-03-03	CRISPR-CAS9 INHIBITORS
IL272888B1 (en)	2023-09-01	Uses of piperidinyl-indole derivatives
LT3607068T (lt)	2023-02-10	Tmprss6 inhibicija, sąlygota rnr interferencijos
IL263050B (en)	2021-09-30	History of Subtirum
IL259796A (en)	2018-07-31	Aza-benzimidazole inhibitors of pad4
IL269409A (en)	2019-11-28	Combinations of chk1- and wee1 - inhibitors
GB201521059D0 (en)	2016-01-13	Inhibitors of metallo-beta-lactamases
IL292245A (en)	2022-06-01	Polymorphic forms of rad1901–2hcl
IL258876B (en)	2022-03-01	Treatment of fatty liver associated with low ovulation
IL272697A (en)	2020-04-30	A polymorphic form of TG02
GB201708457D0 (en)	2017-07-12	Inhibitors of metallo-beta-lactamases
EP3449001A4 (en)	2020-01-01	INHIBITION OF ARNMI MIR-22 BY APT-110
ZA201904460B (en)	2022-05-25	Inhibitors of nhe-mediated antiport
GB201708451D0 (en)	2017-07-12	Inhibitors of metallo-beta-lactamases
EP3716973A4 (en)	2021-11-10	TUMOR METASTASIS INHIBITION METHODS
SG11202101817UA (en)	2021-03-30	Methods of inhibition
AU2017901956A0 (en)	2017-06-08	Inhibition of ferroptosis
GB201721386D0 (en)	2018-01-31	Chrondogy of time-wave
AU2017904351A0 (en)	2017-11-09	Inhibitors of necroptosis
AU2015903172A0 (en)	2015-08-27	Inhibitors of necroptosis
GB201515642D0 (en)	2015-10-21	Enzyme inhibition
GB201515647D0 (en)	2015-10-21	Enzyme inhibition
AU2015900416A0 (en)	2015-02-26	Inhibitors of necroptosis